Background/Aims: High rates of cognitive impairment (CI) are an alarming problem in patients undergoing chronic hemodialysis (HD). Its pathophysiology remains unclear and there are indications that brain ischemia might be one of the key causes. Cerebral tissue oxygenation, as measured by near-infrared spectroscopy, is known to be decreased in HD patients. However, it is unknown whether CI is associated or not associated with lower cerebral oxygenation in these patients. The primary aim of our study was to probe this possible association. Our secondary aim was to assess other factors possibly related to cerebral ischemia and CI. Methods: Thirty-nine patients treated by chronic HD were included in this cross-sectional study. All measurements were performed before the initiation of an HD session. The Montreal Cognitive Assessment (MoCA) was administered according to published recommendations. Regional saturation of oxygen (rSO2) of the left frontal lobe was measured using the INVOS 5100C device. Basic medical history and laboratory data were recorded, and handgrip strength was analyzed. We used the unpaired t test to compare the rSO2 and other variables between cognitively normal patients (MoCA score ≥26) and those who displayed CI (MoCA score <26). Multiple linear regression analysis was used to adjust for principal confounders. Results: Cognitively impaired patients had lower brain rSO2 values compared to cognitively normal patients (48 ± 9 vs. 57 ± 10%, p = 0.01). Among other variables, higher red cell distribution width (15.8 ± 1.9 vs. 13.8 ± 1.6%, p = 0.01) and lower hand grip strength (49.2 ± 23.3 vs. 99.3 ± 31.4 lbs, p < 0.001) also displayed a significant association with CI. The relation between rSO2 and MoCA score was significant after adjustment for age and gender (p = 0.007). Conclusion: Decreased brain oxygenation is associated with weaker cognitive performance in patients undergoing chronic HD. Further understanding the causes of cerebral ischemia in HD patients could lead to the prevention of cognitive decline in this population.

Keywords:
Cerebral oxygenation, Cognitive impairment, Hemodialysis, Hemoglobin saturation, Near-infrared spectroscopy
1.
Murray AM, Tupper DE, Knopman DS, Gilbertson DT, Pederson SL, Li S, Smith GE, Hochhalter AK, Collins AJ, Kane RL: Cognitive impairment in hemodialysis patients is common. Neurology 2006; 67: 216–223.
2.
Etgen T, Chonchol M, Forstl H, Sander D: Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. Am J Nephrol 2012; 35: 474–482.
3.
Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, Allman RM, Warnock DG, McClellan W: Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am J Kidney Dis 2008; 52: 227–234.
4.
Elias MF, Dore GA, Davey A: Kidney disease and cognitive function. Contrib Nephrol 2013; 179: 42–57.
5.
Murray AM: Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis 2008; 15: 123–132.
6.
Van Sandwijk MS, Ten Berge IJ, Majoie CB, Caan MW, De Sonneville LM, Van Gool WA, Bemelman FJ: Cognitive changes in chronic kidney disease and after transplantation. Transplantation 2016; 100: 734–742.
7.
Vega JN, Newhouse PA: Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. Curr Psychiatry Rep 2014; 16: 490.
8.
Sachs GA, Carter R, Holtz LR, Smith F, Stump TE, Tu W, Callahan CM: Cognitive impairment: an independent predictor of excess mortality: a cohort study. Ann Intern Med 2011; 155: 300–308.
9.
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699.
10.
Tiffin-Richards FE, Costa AS, Holschbach B, Frank RD, Vassiliadou A, Kruger T, Kuckuck K, Gross T, Eitner F, Floege J, Schulz JB, Reetz K: The Montreal Cognitive Assessment (MoCA) – a sensitive screening instrument for detecting cognitive impairment in chronic hemodialysis patients. PLoS One 2014; 9: e106700.
11.
Murray AM, Knopman DS: Cognitive impairment in CKD: no longer an occult burden. Am J Kidney Dis 2010; 56: 615–618.
12.
Tholen S, Schmaderer C, Kusmenkov E, Chmielewski S, Forstl H, Kehl V, Heemann U, Baumann M, Grimmer T: Variability of cognitive performance during hemodialysis: standardization of cognitive assessment. Dement Geriatr Cogn Disord 2014; 38: 31–38.
13.
Wolfgram DF, Sunio L, Vogt E, Smith HM, Visotcky A, Laud P, Whittle J: Haemodynamics during dialysis and cognitive performance. Nephrology (Carlton) 2014; 19: 771–776.
14.
Eldehni MT, McIntyre CW: Are there neurological consequences of recurrent intradialytic hypotension? Semin Dial 2012; 25: 253–256.
15.
Prohovnik I, Post J, Uribarri J, Lee H, Sandu O, Langhoff E: Cerebrovascular effects of hemodialysis in chronic kidney disease. J Cereb Blood Flow Metab 2007; 27: 1861–1869.
16.
Khatri M, Wright CB, Nickolas TL, Yoshita M, Paik MC, Kranwinkel G, Sacco RL, DeCarli C: Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke 2007; 38: 3121–3126.
17.
Hoshino T, Ookawara S, Goto S, Miyazawa H, Ito K, Ueda Y, Kaku Y, Hirai K, Nabata A, Mori H, Yoshida I, Tabei K: Evaluation of cerebral oxygenation in patients undergoing long-term hemodialysis. Nephron Clin Pract 2014; 126: 57–61.
18.
Malik J, Kudlicka J, Lachmanova J, Valerianova A, Rocinova K, Bartkova M, Tesar V: Tissue ischemia worsens during hemodialysis in end-stage renal disease patients. J Vasc Access 2017; 18: 47–51.
19.
Markus HS, Lythgoe DJ, Ostegaard L, O'Sullivan M, Williams SC: Reduced cerebral blood flow in white matter in ischaemic leukoaraiosis demonstrated using quantitative exogenous contrast based perfusion MRI. J Neurol Neurosurg Psychiatry 2000; 69: 48–53.
20.
Slater JP, Guarino T, Stack J, Vinod K, Bustami RT, Brown JM 3rd, Rodriguez AL, Magovern CJ, Zaubler T, Freundlich K, Parr GV: Cerebral oxygen desaturation predicts cognitive decline and longer hospital stay after cardiac surgery. Ann Thorac Surg 2009; 87: 36–44; discussion 44–45.
21.
Salazar F, Donate M, Boget T, Bogdanovich A, Basora M, Torres F, Gracia I, Fabregas N: Relationship between intraoperative regional cerebral oxygen saturation trends and cognitive decline after total knee replacement: a post-hoc analysis. BMC Anesthesiol 2014; 14: 58.
22.
Ni C, Xu T, Li N, Tian Y, Han Y, Xue Q, Li M, Guo X: Cerebral oxygen saturation after multiple perioperative influential factors predicts the occurrence of postoperative cognitive dysfunction. BMC Anesthesiol 2015; 15: 156.
23.
Fritz NE, McCarthy CJ, Adamo DE: Handgrip strength as a means of monitoring progression of cognitive decline – a scoping review. Ageing Res Rev 2017; 35: 112–123.
24.
Clouston SA, Brewster P, Kuh D, Richards M, Cooper R, Hardy R, Rubin MS, Hofer SM: The dynamic relationship between physical function and cognition in longitudinal aging cohorts. Epidemiol Rev 2013; 35: 33–50.
25.
Leal VO, Stockler-Pinto MB, Farage NE, Aranha LN, Fouque D, Anjos LA, Mafra D: Handgrip strength and its dialysis determinants in hemodialysis patients. Nutrition 2011; 27: 1125–1129.
26.
Isoyama N, Qureshi AR, Avesani CM, Lindholm B, Barany P, Heimburger O, Cederholm T, Stenvinkel P, Carrero JJ: Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol 2014; 9: 1720–1728.
27.
Kutner NG, Zhang R, Huang Y, McClellan WM, Soltow QA, Lea J: Risk factors for frailty in a large prevalent cohort of hemodialysis patients. Am J Med Sci 2014; 348: 277–282.
28.
McAdams-DeMarco MA, Tan J, Salter ML, Gross A, Meoni LA, Jaar BG, Kao WH, Parekh RS, Segev DL, Sozio SM: Frailty and cognitive function in incident hemodialysis patients. Clin J Am Soc Nephrol 2015; 10: 2181–2189.
29.
Damian AM, Jacobson SA, Hentz JG, Belden CM, Shill HA, Sabbagh MN, Caviness JN, Adler CH: The Montreal Cognitive Assessment and the mini-mental state examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dement Geriatr Cogn Disord 2011; 31: 126–131.
30.
Andro M, Le Squere P, Estivin S, Gentric A: Anaemia and cognitive performances in the elderly: a systematic review. Eur J Neurol 2013; 20: 1234–1240.
31.
Kurella Tamura M, Vittinghoff E, Yang J, Go AS, Seliger SL, Kusek JW, Lash J, Cohen DL, Simon J, Batuman V, Ordonez J, Makos G, Yaffe K: Anemia and risk for cognitive decline in chronic kidney disease. BMC Nephrol 2016; 17: 13.
32.
Ozturk ZA, Unal A, Yigiter R, Yesil Y, Kuyumcu ME, Neyal M, Kepekci Y: Is increased red cell distribution width (RDW) indicating the inflammation in Alzheimer’s disease (AD)? Arch Gerontol Geriatr 2013; 56: 50–54.
33.
Turcato G, Cervellin G, Cappellari M, Bonora A, Zannoni M, Bovi P, Ricci G, Lippi G: Early function decline after ischemic stroke can be predicted by a nomogram based on age, use of thrombolysis, RDW and NIHSS score at admission. J Thromb Thrombolysis 2017; 43: 394–400.
34.
Zhang T, Li J, Lin Y, Yang H, Cao S: Association between red blood cell distribution width and all-cause mortality in chronic kidney disease patients: a systematic review and meta-analysis. Arch Med Res 2017; 48: 378–385.
35.
Vashistha T, Streja E, Molnar MZ, Rhee CM, Moradi H, Soohoo M, Kovesdy CP, Kalantar-Zadeh K: Red cell distribution width and mortality in hemodialysis patients. Am J Kidney Dis 2016; 68: 110–121.
36.
Robertson DA, Savva GM, Kenny RA: Frailty and cognitive impairment – a review of the evidence and causal mechanisms. Ageing Res Rev 2013; 12: 840–851.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.